Empowering Precision Medicine

Cancer is a genetic disease that affects millions of patients and is often difficult and costly to treat. Precise detection of all relevant mutations for patient stratification, prognosis and therapy selection, and precise monitoring of disease development and therapy response are very important to give each patient the best possible outcome.

Our Targeted Locus Amplification (TLA) technology empowers the use of next generation sequencing (NGS) in cancer precision medicine. TLA and its variant FFPE-TLC improve the quality of cancer research, cancer diagnostics and ctDNA liquid biopsy tests.

Complete cancer gene sequencing to detect all relevant mutations

Complete cancer gene sequencing for precise detection of all small and structural mutations is highly relevant for different applications in oncology:

  • Detecting gene fusions with recurrent and novel fusion partners
  • Determining the gene fusion breakpoints at DNA level, which can serve as a robust and sensitive marker for ctDNA monitoring
  • Complete sequencing of tumor suppressor genes to detect all mutations including deletions and promoter/intronic events
  • Analyzing complex rearrangements, genomic events underlying CNVs and novel resistance mechanisms



Robust detection of structural rearrangements remains a challenge, especially in formalin-fixed, paraffin-embedded (FFPE) samples, the routine preservation method for cancer biopsies. TLA employs the inherent DNA crosslinking and fragmentation of FFPE tissue to sequence across much wider genomic regions than standard NGS technologies. The newly developed FFPE-TLC protocol uses the capture enrichment strategy to enhance multiplexing and sensitivity. The PLIER algorithm, developed in parallel, allows for automated detection of structural rearrangements from FFPE-TLC NGS data. This enables:

  • Robust and sensitive detection of rearrangements in solid tumors and lymphomas
  • Clear advantages over FISH and DNA-based NGS
  • Single, DNA-based diagnostic panel tests analyzing SNVs, SVs and CNVs from limited input material
  • A simple, automated bioinformatic workflow without manual curation


For more information on the various oncology applications that we support, please click on a button below.


© 2012-2022 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.